# Retatrutide

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/retatrutide
Canonical HTML page: https://gethealthbrief.com/entity/retatrutide

## Timeline

- **2027**: Regulatory Submissions — Expected window for the first triple-agonist drug applications to the FDA.
- **2026-06-23**: STAT News publishes exposé — Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap.
- **2026-06-23**: White House denial — Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity.
- **2026-04**: Compassionate use request submitted — A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
- **2026-02-24**: Novo Triple-G Phase 2 — Novo Nordisk reports nearly 20% weight loss at 26 weeks.
- **2026**: Phase 3 Expansion — Anticipated start of Novo Nordisk's pivotal late-stage clinical program.
- **2023-Q2**: Lilly Retatrutide Phase 2 — Eli Lilly releases data showing 17.5% weight loss at 24 weeks.

## Recent coverage (4 stories)

### White House Denies 79-Year-Old Trump Received Early Access to Lilly's Retatrutide Under Compassionate Use
2026-06-25 12:26:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments.
Full story: https://gethealthbrief.com/story/white-house-denies-trump-early-access-retatrutide

### Eli Lilly’s Retatrutide Positioned as Next-Gen Obesity Powerhouse by RBC Capital
2026-03-20 05:27:44 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments.
Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver

### Lilly’s Triple-G Retatrutide Hits Phase 3 Diabetes Goal, Lags Mounjaro Slightly
2026-03-19 11:58:18 · Sentiment: Positive · Impact: 8/10 · Sources: 2

Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits.
Full story: https://gethealthbrief.com/story/lilly-triple-g-phase-3-diabetes-data

### Novo Nordisk Triple-G Agonist Challenges Eli Lilly in Obesity Market
2026-02-24 12:06:06 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.
Full story: https://gethealthbrief.com/story/novo-nordisk-triple-g-obesity-trial-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.